Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980694 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Ubiquinol in Huntington Disease
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00980694 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 6 participants.
The verdict
NCT00980694, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals. Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.
Interventions
- DIETARY_SUPPLEMENT ubiquinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980694
The ClinicalTrials.gov registry entry for NCT00980694 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ubiquinol is the first listed.
NCT00980694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00980694 about?
NCT00980694 is a clinical study titled "Bioavailability of Ubiquinol in Huntington Disease". The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free r...
What is the current status of trial NCT00980694?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00980694?
The interventions under investigation include: ubiquinol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00980694?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.